Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S ALLEGRA ALLERGY versus DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S ALLEGRA ALLERGY versus DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE.
CHILDREN'S ALLEGRA ALLERGY vs DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine is a selective peripheral H1-receptor antagonist. It inhibits histamine release from mast cells and basophils, reducing allergic symptoms.
Competitive antagonist of histamine H1 receptors; centrally acting anticholinergic agent that inhibits acetylcholine muscarinic receptors.
Fexofenadine 60 mg orally twice daily or 180 mg once daily.
25 to 50 mg intravenously or intramuscularly every 4 to 6 hours as needed; maximum 400 mg per day.
None Documented
None Documented
Terminal elimination half-life is approximately 14.4 hours (range 11–17 hours) in healthy adults. In children aged 6–12 years, half-life is similar. Clinical context: allows once-daily dosing.
Terminal elimination half-life: 4-10 hours (mean ~8 hours); prolonged in hepatic impairment or elderly (up to 20 hours).
Fexofenadine is excreted primarily unchanged in feces (approximately 80%) and urine (approximately 11%). Biliary excretion accounts for a minor portion.
Primarily renal as inactive metabolites; ~60% of a dose appears in urine as metabolites, with <5% unchanged. Minor biliary/fecal elimination (<10%).
Category C
Category A/B
Antihistamine
Antihistamine